LeMaitre Vascular (LMAT) AI Stock Analysis

A PE of 35.94 on EPS of 2.72 implies investors are paying a premium for LeMaitre Vascular’s earnings, consistent with a quality, growth-oriented medtech name rather than a value stock. However, without explicit revenue and margin trend data, the valuation looks full and assumes continued solid growth and profitability. The current earnings profile appears healthy, but the risk is that any slowdown could pressure this elevated multiple.

• At a share price of $97.75 and EPS of 2.72, the implied PE of 35.94 suggests the market is pricing in above-average growth and durable profitability versus broader medtech/healthcare peers.
• The absolute EPS level indicates the company is meaningfully profitable, but the rich multiple leaves less room for error if revenue growth or margins decelerate.
• Given the limited visibility into recent revenue and margin trends in the data provided, the valuation looks demanding rather than clearly cheap or distressed, supporting a neutral rather than strongly bullish or bearish stance.

The stock is down 14.6% over the last month yet still trades slightly above its 200-day moving average of $94.47, indicating a pullback within an overall longer-term uptrend. Trading modestly above the 200-day suggests the primary trend is intact, but the recent drawdown signals rising near-term selling pressure or profit-taking. Without an oversold RSI level provided, the setup looks more like a consolidation/pause than a clear breakdown or strong buy signal.

• Price of $97.75 versus a 200-day moving average of $94.47 indicates the stock remains in a longer-term uptrend, but only marginally so after the recent correction.
• A 14.6% decline in the last month points to elevated short-term volatility and suggests either a reset from previously stretched levels or growing investor concern.
• The combination of a premium PE and a recent pullback above the 200-day moving average is consistent with a neutral technical stance: not clearly oversold, but no longer at euphoric highs.

Website traffic of roughly 16,784 visitors per month is modest and, in isolation, does not signal a major inflection in commercial momentum. Job openings doubling month over month to 4 roles suggests some incremental investment or selective expansion, but from a very small base. Social media presence is small and largely stagnant, implying limited brand-building via digital channels and no clear sentiment tailwind from online engagement.

• Estimated web traffic at 16,784 visitors per month is relatively low and no growth rate is provided, offering no strong positive or negative signal about demand or pipeline activity.
• Job postings increasing 100% month over month to 4 openings indicates some hiring momentum, but the absolute number is small and may reflect normal staffing rather than aggressive scaling.
• Social media metrics (407 followers on X with 0% growth in 90 days; 429 YouTube subscribers up only 0.9% in 90 days) show minimal digital audience expansion, suggesting limited incremental investor or customer buzz from online channels.

Overall, LeMaitre Vascular’s stock appears fairly valued to slightly expensive, with a recent pullback that has not yet broken its longer-term uptrend. The earnings profile and premium PE imply investors still expect solid growth, but the recent 14.6% decline and muted alternative data signals argue against a strongly bullish stance. On balance, the setup looks neutral: the stock is neither clearly oversold nor fundamentally deteriorating based on the information provided.

• Premium valuation and continued profitability are offset by a recent price correction and the lack of strong growth signals from alternative data.
• The stock trading just above its 200-day moving average after a sharp monthly decline supports a wait-and-see, neutral view rather than a distinctly bullish or bearish call.